Methods	Allocation: random, no further details. Blindness: double, no further details. Duration: 6 weeks. Design: parallel. Location: not reported.
Participants	Diagnosis: schizophrenia or schizoaffective disorder, first episode. N = 42. Sex: not reported. Age: not reported. History: duration ill not reported, age at onset not reported. Setting: inpatient.
Interventions	Olanzapine: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N = 21. Risperidone: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N = 21
Outcomes	Mental State: PANSS total score.
Notes
Risk of bias
Bias	Authors’ judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Random, no further details.
Allocation concealment?	Unclear risk	No further details.
Blinding? subjective outcomes	Unclear risk	Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding
Blinding? objective outcomes	Low risk	Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding
Incomplete outcome data addressed? All outcomes	High risk	Data on subjects leaving the study early were not available.
Free of selective reporting?	High risk	Allowed study medication dose ranges were not indicated. A publication was not available
Free of other bias?	Unclear risk	Insufficient information.